LONG-ACTING FORMS OF HIV PREVENTION

For some people, long-acting forms of HIV prevention may be more desirable than a daily pill.

Antiretroviral-based HIV prevention today — and in the future.

Taking an oral dose of the medication Truvada once a day, every day can prevent HIV infection.

NIAID-funded researchers are developing and testing alternative HIV prevention products that could be inserted, injected or implanted from

ONCE A MONTH...

...TO ONCE A YEAR

in people who commit to use the products on an ongoing basis.

NIAID is funding research on 3 types of long-acting HIV prevention.

- Intravaginal Ring (IVR)
- Implant
- Injectable

How many products are under investigation?

- dapivirine IVR (MTN 025/HOPE and MTN 034/REACH clinical trials)
- Truvada IVR (Oak Crest Institute of Science)
- cabotegravir (SLAP-HIV project)
- dolutegravir (University of North Carolina)
- tenofovir alafenamide (Oak Crest Institute of Science)
- tenofovir alafenamide (SLAP-HIV project)
- tenofovir alafenamide & emtricitabine (Houston Methodist Research Institute)
- cabotegravir (HPTN 077, 083 and 084 clinical trials)

At what stage is this research?

Design  Safety studies  Human studies

For more on the latest advances in HIV prevention research, visit:

NIH National Institute of Allergy and Infectious Diseases

www.niaid.nih.gov  facebook.com/niaid.nih  @NIAIDNews

For more on the latest advances in HIV prevention research, visit: